Skip to content

ANI Pharmaceuticals ANIP Enterprise value

Enterprise value at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$6.34B+33.4%
Viatris logo
ViatrisVTRS
$28.36B+17.7%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$1.35B+176%
ALN
Alnylam PharmaceuticalsALNY
$42.43B+24.1%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$2.01B+78.3%
Amgen logo
AmgenAMGN
$246.43B+9.9%

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.89B+18.3%
P/E20.5×
P/S-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Calculated from ANI Pharmaceuticals’s reported figures.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's enterprise value?
ANI Pharmaceuticals (ANIP) reported enterprise value of $1.72B in Q1 2026.
How has ANI Pharmaceuticals's enterprise value changed year-over-year?
ANI Pharmaceuticals's enterprise value increased by 5.8% year-over-year, from $1.62B to $1.72B.
What is the long-term trend for ANI Pharmaceuticals's enterprise value?
Over 5 years (2020 to 2025), ANI Pharmaceuticals's enterprise value has grown at a 22.2% compound annual growth rate (CAGR), from $662.21M to $1.81B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.